Newsletter · · Ashutosh Agarwal

A Muscarinic Miss in Schizophrenia Reframes the Next Alzheimer's Fight - The Neuro & Alzheimer's Pipeline - Week of August 9, 2026

For the week of August 3 to 9, 2026, the sharpest neuro signal came from psychiatry: a muscarinic miss in schizophrenia pushed Alzheimer's disease psychosis to the front of the queue, Lilly's monster quarter made Kisunla a rounding error, and a practicing neurologist explained why he still will not order the blood test.

The Neuro & Alzheimer's Pipeline

Week of August 3–9, 2026: A Muscarinic Miss in Schizophrenia Reframes the Next Alzheimer's Fight

Week of August 3 – August 9, 2026

The most interesting signal this week did not come from amyloid at all. It came from psychiatry, where a stumble in schizophrenia set up what may be the next real Alzheimer's fight: the psychosis and agitation that wreck patients and families late in the disease. Three threads, clearly sourced, below.

(Quick vocabulary, used throughout: amyloid and tau are the two toxic proteins that build up in an Alzheimer's brain, the target of today's approved drugs. pTau-217 is a form of tau you can now measure from a simple blood draw, the leading blood test for the disease. Muscarinic drugs act on a specific class of brain receptor; they are the hottest non-amyloid idea in brain medicine right now, used first in schizophrenia and now being aimed at Alzheimer's-related psychosis. Cobenfy is the first approved muscarinic drug, from Bristol Myers Squibb. ADP = Alzheimer's Disease Psychosis, the hallucinations, delusions, and agitation that afflict many people in the later stages, a huge unmet need with no great treatment today. GLP-1 drugs are the blockbuster weight-loss and diabetes medicines, e.g. Lilly's Mounjaro and Zepbound.)

TL;DR

  • The loudest neuro news was psychiatry, not Alzheimer's. A muscarinic drug from a company called MapLight missed in schizophrenia, and a top sell-side analyst used the miss to make a bigger point: in brain medicine, how strong a drug is often matters less than you'd think for commercial success, and the real next prize for muscarinics is Alzheimer's psychosis, with data from both Cobenfy (Bristol Myers Squibb) and MapLight due next year.
  • Lilly had a monster quarter, and Alzheimer's was a footnote. Eli Lilly's revenue rose ~48% on the back of weight-loss and diabetes drugs; the CEO called the Alzheimer's work "very compelling" but gave zero specifics. For anyone holding Lilly as an Alzheimer's play, the quarter is a reminder that Kisunla is a call option, not a driver.
  • A practicing neurologist says he won't order the blood test, echoing last week's official guideline. He calls pTau-217 the most specific Alzheimer's marker there is, but refuses to check it in most patients because "many people panic" and "there are no guidelines on what to do" with a high result. That's the demand-side wall for the blood-test companies showing up in a real clinic.

What's new

Psychiatry stumbled, and reframed where the next Alzheimer's fight will be. The meatiest brain-drug discussion this week was on Biotech Hangout (Episode 191, published Aug 3). Paul Matteis, the sell-side biotech analyst who heads therapeutics research at Stifel, walked through a fresh trial from a company called MapLight testing a muscarinic drug in schizophrenia: "this MapLite data came out in schizophrenia for their M1-M4 drug. It did not show the same efficacy as Cobenfy. It did not show the efficacy statistically of a QD [once-daily] formulation, which I think was a hope for differentiation. Tolerability was a little bit better. Retention was a little bit better. But the stock sold off really significantly. It has bounced back some."

Then came the part worth writing down. Matteis argued that raw potency is a poor predictor of who wins in brain medicine:

"How important is effect size? And what does drive commercial success? I would argue effect size is not the best correlate of commercial success in almost any neuroscience category." (Paul Matteis, Biotech Hangout)

And the Alzheimer's kicker: the real arena for these muscarinic drugs may not be schizophrenia at all, but Alzheimer's Disease Psychosis. "In ADP, there's much greater room for MapLite to differentiate given the dosing dynamic with Cobenfy... cautiously optimistic that muscarinics may work in ADP." He noted both Bristol Myers Squibb (with Cobenfy) and MapLight have Alzheimer's-psychosis readouts pushed to next year, and that a second company he covers, which he referred to as Neumora/Nomura Therapeutics, has its own muscarinic ("M4PAM") program with updates later this year. Why it matters: the agitation and psychosis of late-stage Alzheimer's is a massive, poorly served market that the amyloid drugs do nothing for. Muscarinics are the leading non-amyloid shot at it, and this week the whole complex got its first real efficacy data point of the season, a miss in the easier disease (schizophrenia), which raises the stakes for the harder one (Alzheimer's) next year.

Lilly's quarter was enormous, and Alzheimer's was a rounding error. On Stock Market Today With IBD (Aug 5), Ken Shreve, the Investor's Business Daily market commentator, ran through Eli Lilly's (LLY) second-quarter print: earnings up 33%, revenue up 48% (both decelerating from the prior quarter), with the diabetes drug Mounjaro up 91% year over year to $9.9 billion, nearly half of all revenue, and the obesity drug Zepbound up 46% to close to $5 billion. Lilly just started selling its oral weight-loss pill, Fondeo, and bought its way into psychedelic medicines for mental health. On the brain pipeline, all Shreve could relay was the CEO's CNBC soundbite: "the pipeline is still very strong in their neuroscience area. They're doing very compelling work in Alzheimer's, mental health area, oncology." No Kisunla numbers, no launch color, nothing specific. The stock closed up ~4.9% and held its 50-day trend line. Why it moves numbers: if you own Lilly for its anti-amyloid drug Kisunla, this quarter is a splash of cold water, Alzheimer's is invisible in the P&L, drowned out by GLP-1. The Alzheimer's franchise remains a small, optional upside on a stock that lives and dies by weight loss.

A neurologist won't order the blood test, the same wall as last week, now in an actual clinic. On Her Time, Her Health with Dr. Jila (Aug 6), Dr. Majid Fotuhi, a practicing neurologist and author speaking from patient experience, gave the clearest demand-side read of the week on the pTau-217 blood test. He does not undersell the science: "the most reliable and the most specific biomarker for Alzheimer's disease is P-tau-217... these levels of P-tau-217 can start rising 30 years or at least 20 years before a person has any symptoms," comparing it to high cholesterol showing up decades before a heart attack. But then the twist that matters for the diagnostics companies: "I personally prefer not to check it because in my experience, many people panic when they see that this protein is high and they start freaking out that they have Alzheimer's disease... there are no guidelines on what to do with a high P-tau-217." Why it matters: last week the field's official clinical guideline told doctors not to test healthy people. This week a working neurologist said the same thing unprompted, from the exam room, the fattest imagined market (screening the worried-well) keeps hitting the same wall, now from an actual clinician, not just a committee. His parting optimism is worth logging too: within "five to 10 years, we will look at Alzheimer's disease much the way we look at diabetes, a condition that can be prevented, managed, and treated successfully with a combination of medications and lifestyle factors."

The debate

Does under-the-skin dosing plus cheap blood tests plus broader coverage finally turn anti-amyloid (and eventually anti-tau) into a multi-billion-dollar franchise, or do modest benefit, brain-bleed risk, and diagnostic bottlenecks keep uptake weak while the tau bets stay unproven?

Bull: Nothing this week weakened the long-term case, and the pipeline just got wider. Muscarinics are advancing on a second front, Alzheimer's psychosis, that the amyloid drugs can't touch, so the total brain-disease opportunity is growing, not shrinking. A respected neurologist reaffirmed that the blood test genuinely sees the disease coming decades early and openly predicted Alzheimer's becomes a managed condition like diabetes. And Lilly, the most important company in the space, is a cash machine funding whatever brain bets it likes.

Bear: Look at what actually happened. The one hard efficacy data point of the week was a miss, a muscarinic drug that couldn't match the approved one or prove its convenience angle, a reminder that CNS trials fail more than they succeed, and the Alzheimer's-psychosis readouts everyone's waiting on are still a year away. The blood-test wall got taller, not shorter: a practicing doctor won't even order the test because there's nothing to do with the answer and patients panic. And Lilly's quarter quietly said the quiet part out loud, Kisunla is so small it didn't merit a number. Widening pipeline, sure; near-term commercial engine, still stuck.

Net: the bull case gained optionality (muscarinics opening the psychosis front) but no new evidence; the bear case gained another real-world brick on the diagnostics wall. The re-rating catalysts for this whole complex are unchanged and still ahead: Medicare coverage plus a guideline that green-lights broader blood testing, hard Kisunla and Leqembi sales numbers, and the muscarinic Alzheimer's-psychosis data due in 2027.

Stocks in play

  • LLY (Eli Lilly): Bull: a genuine juggernaut, revenue +48%, Mounjaro +91% to $9.9B, Zepbound +46% to ~$5B, a new oral weight-loss pill (Fondeo) now selling, with an Alzheimer's drug (Kisunla) as free upside and the balance sheet to fund any brain bet it wants; CEO calls the Alzheimer's work "very compelling." Bear: the Alzheimer's franchise is invisible in the numbers and got no specifics this week; growth is decelerating; the stock trades on GLP-1, so Kisunla is a rounding error, not a thesis. Next catalyst: the next actual Kisunla launch metrics. (Stock Market Today With IBD, Aug 5)
  • BMY (Bristol Myers Squibb): Bull: owns Cobenfy, the first approved muscarinic drug and the benchmark the whole class is measured against; a rival's schizophrenia miss this week makes Cobenfy look better by comparison, and its Alzheimer's-psychosis readout next year could open a large new market the amyloid drugs can't reach. Bear: the Alzheimer's-psychosis data is a year out and "not without risk" per the analyst; muscarinics are still unproven in Alzheimer's, and effect size may not even be what drives adoption. Next catalyst: Cobenfy's Alzheimer's-psychosis (ADP) trial readout, expected next year. (Biotech Hangout, Aug 3)
  • MapLight (private, not confidently ticker-mapped): Bull: its M1-M4 muscarinic drug showed slightly better tolerability and retention than the benchmark, and the analyst sees "much greater room to differentiate" in Alzheimer's psychosis than in schizophrenia; the stock already sold off and bounced, so expectations are reset. Bear: it just missed in schizophrenia on both efficacy and its once-daily convenience pitch, the exact places it needed to win. Next catalyst: its Alzheimer's-psychosis data, expected next year. (Named on Biotech Hangout, Aug 3; a public ticker could not be confirmed, so treat as a watch item, not a tradable name.)
  • Neumora / "Nomura" Therapeutics (as named by the host, not confidently ticker-mapped): Bull: has its own muscarinic ("M4PAM") franchise with updates coming later this year, a third shot on the non-amyloid CNS goal. Bear: early-stage, and the whole muscarinic thesis just took an efficacy scare in schizophrenia. Next catalyst: the promised program update later this year. (Biotech Hangout, Aug 3)
  • Blood-diagnostics complex (QTRX / Quanterix, C2N, Roche, LH / LabCorp, DGX / Quest), read-through only: Bull: a respected neurologist reaffirmed pTau-217 as the single most specific Alzheimer's marker, detectable decades before symptoms. Bear: that same neurologist won't order it in practice, patients panic and there's no guideline for the result, echoing last week's official "don't screen the healthy." Next catalyst: Medicare coverage and/or a guideline that green-lights broader testing. (Her Time, Her Health, Aug 6)

Read-throughs

  • Blood diagnostics (QTRX, C2N, Roche, LH, DGX): the demand-side wall keeps getting real-world confirmation. The pattern from last week held: the science is great, the permission isn't there. This week a practicing neurologist, unprompted, refused to order pTau-217 in most patients, "no guidelines on what to do," and patients "panic." Near-term, these names live off symptomatic testing ordered by specialists, not mass screening of the worried-well. Watch guideline changes as closely as any CMS decision. (Her Time, Her Health, Aug 6)
  • Muscarinics are the non-amyloid theme to track, and Alzheimer's psychosis is the AD-adjacent prize. The schizophrenia miss this week doesn't kill the class; it sharpens the question of whether these drugs can win in Alzheimer's-related psychosis and agitation, a large market with essentially no good option today. BMY (Cobenfy) is the incumbent; MapLight and the "M4PAM" player are the challengers; all the meaningful Alzheimer's data lands next year. This is the freshest genuinely investable neuro storyline of the week. (Biotech Hangout, Aug 3)
  • Lilly as an Alzheimer's proxy, don't. The quarter is a clean reminder: LLY is a GLP-1 stock with a brain-drug lottery ticket attached. If your Kisunla thesis needs Lilly's stock to reflect it, this quarter says it won't for a long while. (Stock Market Today With IBD, Aug 5)

What changed vs last week

Last week was a rich, detailed recap of the field's big annual conference: the tau drug that reversed tangles but failed its own test, the blood test that predicts a decade of risk but the guidelines won't recommend, the first dosed patient in a combination trial.

What actually moved: the conversation shifted sideways, from amyloid and tau to muscarinics and psychiatry, a mechanism that isn't in last week's story at all. The one hard data point of the week (a schizophrenia miss) came from that corner, and it set up Alzheimer's-psychosis as a 2027 event to watch. On diagnostics, there was no new science, but the "don't test the healthy" message got a second, independent voice, a practicing neurologist this time, not a guideline committee. And Lilly reported a huge quarter in which Alzheimer's earned one vague sentence. The referees that matter, a Medicare coverage decision, a guideline expansion, hard sales prints, and the 2027 muscarinic Alzheimer's-psychosis data, are all still ahead.